L. Gramegna

What is the normal range for N-terminal pro-brain natriuretic peptide ? How well does this normal range screen for cardiovascular disease ?

G. Nollo, M. Centonze, F. Ravelli, 2005 .

Risk Identification in Arrhythmic Athletes with Fatal or Resuscitated Cardiac Arrest

G. Thiene, G. Inama, M. Barbareschi, 2005 .

Catheter Ablation of Wolff-Parkinson-White Syndrome Associated with Congenital Absence of Inferior Vena Cava

G. Inama, F. Furlanello, G. Vergara, 1998, Journal of Interventional Cardiac Electrophysiology.

Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.

A. Proclemer, D. Muser, P. Mazzone, 2013, International journal of cardiology.

In-hospital follow-up of implantable cardioverter defibrillator and pacemaker carriers: patients' inconvenience and points of view. A four-hospital Italian survey.

G. Gasparini, F. Zanon, L. Tomasi, 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

How To Choose Between Single-Chamber and Dual-Chamber ICD

M. Disertori, M. Marini, M. Greco, 2007 .

Antitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry

A. Capucci, G. Boriani, G. Inama, 2001 .